Reply to Commentary by Cummings (2022): Surrogate endpoints extend beyond biomarkers

Reply to Commentary by Cummings (2022): Surrogate endpoints extend beyond biomarkers

Bibliographic Details
Main Authors:	Anthony Muchai Manyara, Oriana Ciani, Rod S. Taylor
Format:	Article
Language:	English
Published:	Wiley 2022-01-01
Series:	Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Online Access:	https://doi.org/10.1002/trc2.12344

Similar Items

A call for better reporting of trials using surrogate primary endpoints
by: Anthony Muchai Manyara, et al.
Published: (2022-01-01)

Scoping and targeted reviews to support development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: protocol
by: Derek Stewart, et al.
Published: (2022-10-01)

Surrogate endpoints in trials: a call for better reporting
by: Oriana Ciani, et al.
Published: (2022-12-01)

Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE
by: Martin Offringa, et al.
Published: (2022-10-01)

Biomarkers and surrogate endpoints.
by: Aronson, J
Published: (2005)

Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE
by: Manyara, AM, et al.
Published: (2022)

Biomarkers and Surrogate Endpoints in Monitoring Therapeutic Interventions
by: Aronson, J
Published: (2008)

Significance of biomarkers and surrogate endpoints in preclinical and clinical trials
by: Ilić Katarina, et al.
Published: (2007-01-01)

Commentary on: A call for better reporting of trials using surrogate primary endpoints
by: Jeffrey Cummings
Published: (2022-01-01)

A framework for the definition and interpretation of the use of surrogate endpoints in interventional trialsResearch in context
by: Oriana Ciani, et al.
Published: (2023-11-01)

A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials
by: Ciani, O, et al.
Published: (2023)

Simple Methods for Evaluating 4 Types of Biomarkers: Surrogate Endpoint, Prognostic, Predictive, and Cancer Screening
by: Stuart G Baker, et al.
Published: (2020-07-01)

Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction
by: Gianluigi Savarese, et al.
Published: (2022-08-01)

Surrogate endpoints for neonatal outcome: A rapid review
by: Shiraz El Adam, et al.
Published: (2024-08-01)

Quetiapine-Related Deaths: In Search of a Surrogate Endpoint
by: Ivan Šoša
Published: (2024-01-01)

Defining surrogate endpoints for clinical trials in severe Falciparum malaria.
by: Jeeyapant, A, et al.
Published: (2017)

Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.
by: Lassere, M, et al.
Published: (2007)

Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990–2011
by: Behnood Bikdeli, et al.
Published: (2017-03-01)

Commentary: Visual attention is not deployed at the endpoint of averaging saccades
by: Stefan Van der Stigchel, et al.
Published: (2018-11-01)

A meta-analysis of GFR slope as a surrogate endpoint for kidney failure
by: Inker, LA, et al.
Published: (2023)

Rationale for surrogate endpoints and conditional marketing authorization of new therapies for kidney transplantation
by: Naesens, M, et al.
Published: (2022)

Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints
by: Wenbo Zhu, et al.
Published: (2017-09-01)

Appropriate Surrogate Endpoint in Drug-Coated Balloon Trials for Coronary Artery Diseases
by: Xinyue Lang, et al.
Published: (2022-06-01)

The use of surrogate endpoints in regulating medicines for cardio-renal disease: opinions of stakeholders.
by: Bauke Schievink, et al.
Published: (2014-01-01)

Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines
by: Jianyang Liu, et al.
Published: (2022-04-01)

Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study
by: Joshua D. Wallach, et al.
Published: (2018-03-01)

Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers.
by: Hugosson, J, et al.
Published: (2001)

Simulation studies of surrogate endpoint validation using single trial and multitrial statistical approaches.
by: Lassere, M, et al.
Published: (2007)

Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm
by: Charlotte Pawlyn, et al.
Published: (2024-08-01)

Time to clinical improvement: an appropriate surrogate endpoint for pulmonary arterial hypertension medication trials
by: An Wang, et al.
Published: (2023-06-01)

An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse.
by: Patrick P J Phillips, et al.
Published: (2013-01-01)

Impact of a clinical pharmacist on a cardiovascular surrogate endpoint: a pilot study
by: Ripley TL, et al.
Published: (2012-09-01)

Knowledge, perceptions and practices towards diabetes risk in sub-Saharan Africa: a mixed-methods scoping review
by: Anthony Muchai Manyara, et al.
Published: (2024-01-01)

Beyond the Keynesian endpoint : crushed by credit and deceived by debt -- how to revive the global economy /
by: Crescenzi, Anthony
Published: (c201)

Corrigendum: Time to clinical improvement: an appropriate surrogate endpoint for pulmonary arterial hypertension medication trials
by: An Wang, et al.
Published: (2024-02-01)

Evaluation of Surrogate Endpoints Using Information-Theoretic Measure of Association Based on Havrda and Charvat Entropy
by: María del Carmen Pardo, et al.
Published: (2022-01-01)

An alternative trial-level measure for evaluating failure-time surrogate endpoints based on prediction error
by: Shaima Belhechmi, et al.
Published: (2019-09-01)

Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint
by: Zewei Zhang, et al.
Published: (2023-02-01)

Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series
by: Michael S. Yule, et al.
Published: (2024-06-01)

Reply to Commentary on “Classification(s) of Cervical Deformity”
by: Austin C. Kaidi, et al.
Published: (2023-03-01)